Treatment of chronic myeloid leukemia in the imatinib era

Aziz, Zeba; Iqbal, Javaid; Akram, Mohammad; Saeed, Shahzad

doi:10.1002/cncr.22498

Cited by 45 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a large multi-center study in France reported the frequencies of CP, AP and BC as 96.8%, 2.2% and 0.9%, respectively, at the time of diagnosis [18]. Therefore, our data strongly correlate with the data previously reported for Pakistan [20] and one possible explanation for this similarity may be that Pakistan is a neighboring country with similar ethnic demography and sociocultural factors.…”

Section: Resultssupporting

confidence: 87%

Phase distribution of chronic myeloid leukemia in Bangladesh

et al. 2014

View full text Add to dashboard Cite

BackgroundHere, we report the phase distribution of chronic myeloid leukemia (CML), defined based on the World Health Organization criteria, among 63 patients in Bangladesh. All patients were diagnosed based on complete blood count, bone marrow examination including bone marrow aspiration and reverse-transcriptase polymerase chain reaction (RT-PCR). Out of 63 patients, 42 were male and 21 were female. The mean age of the subjects was 37.4 years, with an age range of 17-60 years. The majority of patients (86%) were classified in the chronic phase (CP), 7 (11%) in the accelerated phase (AP) and two (3%) in blast crisis (BC). The most frequent patient age ranges were 21-30 years for CP, 41-50 years for AP and 41-50 years for BC.ResultsThe Philadelphia chromosome was detected in 48 patients by RT-PCR. The mean total leukocyte counts, platelet counts, hemoglobin levels and marrow blast frequencies were 101 × 109/L, 409 × 109/L, 12.2 g/dl and 2.8% for CP; 121 × 109/L, 418 × 109/L, 8.7 g/dl and 15% for AP and 311 × 109/L, 396 × 109/L, 9.2 g/dl and 26% for BC, respectively.ConclusionThis study concluded that most CML patients in Bangladesh are from a younger age group (31-40 years). In addition, males were more commonly affected, although females were afflicted with this disease at a younger age.

show abstract

Section: Resultssupporting

confidence: 87%

Phase distribution of chronic myeloid leukemia in Bangladesh

et al. 2014

View full text Add to dashboard Cite

show abstract

“…We have previously reported marked improvements in cytogenetic response and sustained survival at longer follow-up with IM in our patients from Pakistan [3,7]. However, there is a paucity of data from developing countries on the long-term impact on QOL and the degree of comorbidity in patients receiving IM for the treatment of CP-CML.…”

Section: Introductionmentioning

confidence: 86%

“…Also, SCT can only be performed in a limited number of patients in Pakistan because the majority belong to a poor socioeconomic class and, hence, cannot afford to undergo the procedure. Moreover, poor living conditions and illiteracy put them at risk of recurrent infections [3]. Other treatment options have included hydroxyurea, which has few sideeffects but is of limited efficacy [2].…”

Section: Introductionmentioning

confidence: 99%

Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia

Aziz

Iqbal

Aaqib

et al. 2011

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

Imatinib mesylate (IM) is a first-line treatment of chronic phase-chronic myeloid leukemia (CP-CML). The primary objective of this study was to assess the quality of life (QOL) in patients with CP-CML treated with IM. Ninety patients with newly diagnosed CP-CML were assessed for QOL with first-line IM. Patients completed the cancer-specific FACT-BRM questionnaire (functional assessment of cancer therapy-biologic response modifiers) at baseline and at 3 and 6 months. FACT-BRM consists of subscales including physical well-being (PWB), social and family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), BRM-physical, and BRM-mental. The primary endpoint was the Trial Outcome Index (TOI), created as a measure of physical function and well-being. An increase of ≥5 from baseline was considered to be a clinically significant improvement. The mean TOI score increased from 75.5 at baseline to 85.2 (p<0.0001) at 6 months, representing a healthy QOL. When comparing the individual TOI subscales, there was a mean increase of 16.4 in the daily functioning and well-being score, and a mean decrease of 6.2, 4.9, and 16.1 was noted in fatigue, emotional/cognitive dysfunction, and side-effects scores at 6 months, respectively. Improvement was not affected by age, sex, or Sokal score. With prolonged treatment, IM results in a higher physical well-being, less fatigue and emotional and cognitive dysfunction, and very few side-effects.

show abstract

“…It is therefore important to establish if these results can be reproduced in Asian developing countries. A recently published trial from Pakistan shows a favorable result, similar to Western counties [4]. However, the efficacy of IM in Indian patients seems poorer [5].…”

Section: Introductionmentioning

confidence: 93%

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

et al. 2009

View full text Add to dashboard Cite

There is limited data from developing countries on the current status of imatinib treatment for chronic myeloid leukemia (CML), thus we retrospectively analyzed 116 Chinese CML patients who received imatinib between 2003 and 2008. The response rates for 102 patients in chronic phase were: complete hematologic, 94.1%; complete cytogenetic, 69.6%; and complete molecular response, 54.9%. For 14 patients in the accelerated phase, the respective response rates were 85.7, 35.7 and 28.6%. The 3-year progression-free survival and 5-year overall survival were 73.3 and 74.8%. Although skin hypopigmentation occurs as the most common side effect (77.6%), imatinib is still well tolerated. In addition to the known pretreatment characteristics of spleen size, leukocyte and platelet counts, disease phase and Sokal scores, we found that delayed therapy, variant Philadelphia chromosome translocations and IM-related grade 3/4 leucopenia were associated with an inferior cytogenetic response. Four factors emerged as predictors of disease progression: molecular response, cytogenetic response, disease phase and disease duration prior to imatinib treatment, but only the latter three remained significant after multivariate analysis. The results indicate that the suboptimal outcome in Chinese patients is associated with delayed imatinib therapy, so the importance of the optimal treatment opportunity for CML should be emphasized.

show abstract

Treatment of chronic myeloid leukemia in the imatinib era

Cited by 45 publications

References 44 publications

Phase distribution of chronic myeloid leukemia in Bangladesh

Phase distribution of chronic myeloid leukemia in Bangladesh

Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

Contact Info

Product

Resources

About